Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.

Neuroscience letters - 14 Aug 2006

Religa D, Czyzewski K, Styczynska M, Peplonska B, Lokk J, Chodakowska-Zebrowska M, Stepien K, Winblad B, Barcikowska M

Abstract excerpt

Elevated levels of homocysteine have been observed in Parkinson's disease (PD) patients treated with levodopa. However, it is not studied if duration of PD or PD per se is associated with hyperhomocysteinemia. In the present study, the levels of homocysteine in 99 levodopa-treated PD patients, 15...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Folic Acid
Share to Homocysteine
Share to Hyperhomocysteinemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Levodopa

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Parkinson Disease

Share to Reference Values

Share to Vitamin B 12

Source

Identifiers

PMID: 16787708
DOI: 10.1016/j.neulet.2006.05.040

Genes

MTHFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16787708-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.PMID 16787708Read ↗

Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.Semantic proximity Read ↗

Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapySemantic proximity Read ↗

Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.Semantic proximity Read ↗

Association of MTHFR C677T with total homocysteine plasma levels and susceptibility to Parkinson's disease: a meta-analysis.Semantic proximity Read ↗

Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase C677T genotype and PD.Semantic proximity Read ↗

Homocysteine levels, genetic background, and cognitive impairment in Parkinson's disease.Semantic proximity Read ↗

Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.Semantic proximity Read ↗

Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic studySemantic proximity Read ↗

The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease.Semantic proximity Read ↗

Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T Polymorphism in Levodopa-treated Parkinson’s Disease PatientsSemantic proximity Read ↗

Association of MTHFR, MTR, and MTRR polymorphisms with Parkinson's disease among ethnic Chinese in Taiwan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.